- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03847948
Biological Factors Associated With Subclinical Valvular Thrombosis (START)
Evaluation of Biological Factors Associated With Subclinical Valvular Thrombosis in pAtients With Severe aoRtic Stenosis Undergoing TAVI: START Trial
A prospective, multicentric cohort study including 166 patients with symptomatic aortic stenosis treated with transcatheter aortic valve implantation (TAVI).
- The main objective is to determine whether the high residual platelet reactivity rates in patients undergoing TAVI is associated with the occurrence of clinical and / or subclinical prosthetic valve thrombosis measured by echocardiography and multi-slice computerized tomography
Study Overview
Status
Conditions
Detailed Description
For the purpose of the study, platelet reactivity will be measured with the commercial kit PLT VASP/P2Y12 at baseline, 1day and 3 months postprocedure.
Secondary objectives include: -Determine the variability of platelet aggregation measured at baseline before the procedure, 1-day post-procedure and at 3-6 and 1 year follow-up.
- To determine whether the pro-thrombotic inflammatory response measured by the CD14 + and CD16 + quantification observed after TAVI is associated with the appearance of prosthetic thrombosis.
- To evaluate the Correlation of Von Willebrand factor levels and distribution of Von Willebrand multimers with the appearance of prosthetic thrombosis at baseline before the procedure, 1-day post-procedure and at 3, 6 months follow-up and 1 year.
- To determine whether the residual platelet reactivity rates in patients undergoing TAVI are associated with the occurrence of clinical events, at baseline before the procedure, 1-day post-procedure and at 3,6 months follow-up and 1 year
- To evaluate the clinical factors associated with the appearance of early prosthetic thrombosis.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Not yet recruiting
- Hospital Clínic
-
Contact:
- Ander Regueiro, MD, PhD
- Email: anderregueiro@gmail.com
-
Madrid, Spain, 28040
- Recruiting
- Hospital Clínico San Carlos
-
Contact:
- Pilar Jimenez Quevedo, MD, PhD
- Phone Number: 34-9-1330-3283
- Email: patrop@telefonica.net
-
Contact:
- Esther Bernado, Drs
- Email: ebernardogarcia@yahoo.es
-
Principal Investigator:
- Pilar Jimenez Quevedo, MD, PhD
-
Principal Investigator:
- maria del Trigo, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with severe symptomatic aortic stenosis who it was accepted to be treated with TAVI by a multidisciplinary team "Heat Team".
- TAVI was successfully implanted (according to Valve Academic Research Consortium II criteria) and are under treatment with double antiplatelet therapy.
- Signed informed consent to participate in this study.
Exclusion Criteria:
- Age under 18 years and pregnant or of childbearing age.
- Acute Recent stroke recent <14 days before TAVI.
- The patients with proven allergy to aspirin, clopidogrel
- Patients that after TAVI cannot undergo a double antiplatelet regimen for 6 months due to a new post-TAVI medical indication or are anticoagulated.
- Knowledge of pregnancy or lactation Thrombocytopenia (<50,000 platelets U / L) well documented and clinically relevant.
- The patients with documented moderate or severe hepatic insufficiency
- Severe chronic renal insufficiency with creatinine clearance <30 ml / min.
- The patients who can not attend the follow-up visits scheduled in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The association between high residual platelet reactivity rates in patients undergoing TAVI with the occurrence of clinical and / or subclinical prosthetic valve thrombosis
Time Frame: at 3 months
|
platelet reactivity will be measured with the commercial kit platelet Vasodilator Stimulated Phosphoprotein (VASP)/P2Y12 and subclinical valve thrombosis by transthoracic echocardiography and multi-slice computerized tomography
|
at 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure the variability of platelet aggregation
Time Frame: at baseline, 1 day post-procedure and at 3-6 months and 1 year follow-up.
|
platelet aggregation
|
at baseline, 1 day post-procedure and at 3-6 months and 1 year follow-up.
|
To quantify the pro-thrombotic inflammatory response
Time Frame: at baseline, 1 day post-procedure and at 3, 6 months and 1 year follow-up.
|
measured by serum levels of (cluster of differentiation 14) CD14 + and (cluster of differentiation 16) CD16 +
|
at baseline, 1 day post-procedure and at 3, 6 months and 1 year follow-up.
|
To correlate of Von Willebrand factor levels and distribution of Von Willebrand factor multimers with the appearance of prosthetic thrombosis
Time Frame: at baseline, 1 day post-procedure and at 3, 6 months and 1 year follow-up.
|
Serum Von Willebrand factor levels and distribution of Von Willebrand factor multimers with the appearance of prosthetic thrombosis assessed by transthoracic echocardiography or multi-slice computerized tomography
|
at baseline, 1 day post-procedure and at 3, 6 months and 1 year follow-up.
|
To correlate residual platelet reactivity with clinical events
Time Frame: at baseline, 1 day post-procedure and at 3, 6 months and 1 year follow-up.
|
platelet aggregation
|
at baseline, 1 day post-procedure and at 3, 6 months and 1 year follow-up.
|
To evaluate clinical factors associated with the appearance of early prosthetic thrombosis.
Time Frame: multi slice computerized tomography at 3 month and clinical up to 1 year.
|
to perform Multislice computerized tomography and clinical follow-up
|
multi slice computerized tomography at 3 month and clinical up to 1 year.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI17/01685
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Pan XiangbinRecruiting